ZA201308329B - Radiolabelled glutaminyl cyclase inhibitors - Google Patents
Radiolabelled glutaminyl cyclase inhibitorsInfo
- Publication number
- ZA201308329B ZA201308329B ZA2013/08329A ZA201308329A ZA201308329B ZA 201308329 B ZA201308329 B ZA 201308329B ZA 2013/08329 A ZA2013/08329 A ZA 2013/08329A ZA 201308329 A ZA201308329 A ZA 201308329A ZA 201308329 B ZA201308329 B ZA 201308329B
- Authority
- ZA
- South Africa
- Prior art keywords
- glutaminyl cyclase
- cyclase inhibitors
- radiolabelled
- radiolabelled glutaminyl
- inhibitors
- Prior art date
Links
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 title 1
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490654P | 2011-05-27 | 2011-05-27 | |
| PCT/EP2012/059649 WO2012163773A1 (en) | 2011-05-27 | 2012-05-24 | Radiolabelled glutaminyl cyclase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201308329B true ZA201308329B (en) | 2015-02-25 |
Family
ID=46149465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/08329A ZA201308329B (en) | 2011-05-27 | 2013-11-06 | Radiolabelled glutaminyl cyclase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8945510B2 (enExample) |
| EP (1) | EP2714098A1 (enExample) |
| JP (1) | JP2014515364A (enExample) |
| KR (1) | KR20140028076A (enExample) |
| CN (1) | CN103561776B (enExample) |
| AU (1) | AU2012264951A1 (enExample) |
| BR (1) | BR112013030341A2 (enExample) |
| CA (1) | CA2835014A1 (enExample) |
| EA (1) | EA028533B1 (enExample) |
| IL (1) | IL229187A (enExample) |
| MX (1) | MX2013013946A (enExample) |
| SG (2) | SG194770A1 (enExample) |
| WO (1) | WO2012163773A1 (enExample) |
| ZA (1) | ZA201308329B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6454651B2 (ja) | 2013-03-15 | 2019-01-23 | プロビオドルグ エージー | 新規阻害剤 |
| CN104230778B (zh) * | 2014-07-14 | 2017-01-04 | 大连大学 | β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法 |
| CR20170076A (es) | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| CA3106239A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| KR102230832B1 (ko) * | 2019-06-17 | 2021-03-24 | (주) 메디프론디비티 | N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2020408107B2 (en) | 2019-12-20 | 2026-04-23 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1250834B (enExample) | 1963-01-09 | |||
| US5304367A (en) * | 1990-11-16 | 1994-04-19 | New York University | In vivo brain imaging agent and method for diagnosis of psychiatric disorders |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| KR101099206B1 (ko) * | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| EP2021340B1 (en) | 2006-04-21 | 2014-07-23 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US8278345B2 (en) * | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5677297B2 (ja) * | 2008-07-31 | 2015-02-25 | プロビオドルグ エージー | 神経変性疾患の診断／予後判定の指標としてのグルタミニルシクラーゼ |
| SG193828A1 (en) | 2008-09-04 | 2013-10-30 | Probiodrug Ag | Novel inhibitors |
| EP2411057B1 (en) | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| US8269019B2 (en) * | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
-
2012
- 2012-05-24 JP JP2014511862A patent/JP2014515364A/ja active Pending
- 2012-05-24 MX MX2013013946A patent/MX2013013946A/es unknown
- 2012-05-24 EA EA201301334A patent/EA028533B1/ru not_active IP Right Cessation
- 2012-05-24 CN CN201280025603.6A patent/CN103561776B/zh not_active Expired - Fee Related
- 2012-05-24 SG SG2013081567A patent/SG194770A1/en unknown
- 2012-05-24 US US13/479,826 patent/US8945510B2/en not_active Expired - Fee Related
- 2012-05-24 BR BR112013030341A patent/BR112013030341A2/pt not_active IP Right Cessation
- 2012-05-24 AU AU2012264951A patent/AU2012264951A1/en not_active Abandoned
- 2012-05-24 EP EP12723476.3A patent/EP2714098A1/en not_active Withdrawn
- 2012-05-24 SG SG10201604304RA patent/SG10201604304RA/en unknown
- 2012-05-24 KR KR20137033449A patent/KR20140028076A/ko not_active Withdrawn
- 2012-05-24 WO PCT/EP2012/059649 patent/WO2012163773A1/en not_active Ceased
- 2012-05-24 CA CA 2835014 patent/CA2835014A1/en not_active Abandoned
-
2013
- 2013-10-31 IL IL229187A patent/IL229187A/en not_active IP Right Cessation
- 2013-11-06 ZA ZA2013/08329A patent/ZA201308329B/en unknown
-
2014
- 2014-12-15 US US14/570,350 patent/US9610368B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140028076A (ko) | 2014-03-07 |
| EP2714098A1 (en) | 2014-04-09 |
| CN103561776A (zh) | 2014-02-05 |
| BR112013030341A2 (pt) | 2016-11-29 |
| SG10201604304RA (en) | 2016-07-28 |
| MX2013013946A (es) | 2014-01-31 |
| IL229187A (en) | 2017-04-30 |
| US9610368B2 (en) | 2017-04-04 |
| CN103561776B (zh) | 2016-08-31 |
| CA2835014A1 (en) | 2012-12-06 |
| WO2012163773A1 (en) | 2012-12-06 |
| NZ617581A (en) | 2016-03-31 |
| US20120301398A1 (en) | 2012-11-29 |
| SG194770A1 (en) | 2013-12-30 |
| EA028533B1 (ru) | 2017-11-30 |
| US20150104389A1 (en) | 2015-04-16 |
| EA201301334A1 (ru) | 2014-05-30 |
| IL229187A0 (en) | 2013-12-31 |
| JP2014515364A (ja) | 2014-06-30 |
| US8945510B2 (en) | 2015-02-03 |
| AU2012264951A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273079B (en) | Heterocycloamines as pi3k inhibitors | |
| IL229187A0 (en) | Radiolabeled glutaminyl cyclase inhibitors | |
| ZA201307016B (en) | Glucosylceramide synthase inhibitors | |
| PL2710007T3 (pl) | Inhibitory kinazy | |
| ZA201404156B (en) | Kinase inhibitors | |
| IL229028A0 (en) | Kinase inhibitors | |
| EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
| GB201009731D0 (en) | Kinase inhibitors | |
| ZA201404157B (en) | Kinase inhibitors | |
| GB201216884D0 (en) | Composition | |
| GB201112157D0 (en) | New use of glutaminyl cyclase inhibitors | |
| GB201018597D0 (en) | Inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| SG10201602021WA (en) | Glucosylceramide synthase inhibitors |